• FDA Issues Complete Response Letter for Ryaltris americanpharmaceuticalreview
    June 26, 2019
    India generic drug manufacturer, Glenmark, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), Nasal Spray.
  • FDA Issues Complete Response Letter for NDA for Dasotraline americanpharmaceuticalreview
    September 03, 2018
PharmaSources Customer Service